BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gozanertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gozanertinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05532696-2326@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Gozanertinib: Phase 1/2 readout est. (NCT05532696)
DESCRIPTION:Gozanertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients\nEs
 timated primary completion: November 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gozanertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05532696
URL:https://assetmemo.bio/drug/gozanertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
